Aadvances in the development of biologics to treat drug addictions and overdose;Avances en el desarrollo de productos biológicos para el tratamiento de la adicción a las drogas y las sobredosis

Adicciones

Volumn 24, Issue 2, 2012, Pages 95-104

  Montoya, Iván D ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Antibodies; Biologics; Drug abuse; Enzymes; Overdose; Vaccines

Indexed keywords

BIOLOGICAL PRODUCT; COCAINE; NARCOTIC ANALGESIC AGENT;

ADDICTION; COCAINE DEPENDENCE; HUMAN; INTOXICATION; OPIATE ADDICTION; REVIEW;

ANALGESICS, OPIOID; BIOLOGICAL AGENTS; COCAINE; COCAINE-RELATED DISORDERS; HUMANS; OPIOID-RELATED DISORDERS; OVERDOSE; SUBSTANCE-RELATED DISORDERS;

EID: 84861843662     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.101     Document Type: Article

References (49)

1. Anton, B., & Leff, P. (2006). A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine, 24, 3232-3240.
2. Anton, B., Salazar, A., Flores, A., Matus, M., Marin, R., Hernandez, J. A., & Leff P. (2009). Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Human Vaccine, 5, 214-229.
3. Bonese, K. F., Wainer, B. H., Fitch, F. W., Rothberg, R. M., & Schuster, C. R. (1974). Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature, 252, 708-710.
4. Brimijoin, S., Gao, Y., Anker, J. J., Gliddon, L. A., LaFleur, D., Shah, R....Carroll, M. E. (2008). A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology, 33, 2715-2725.
5. Carroll, F. I., Abraham, P., Gong, P. K., Pidaparthi, R. R., Blough, B. E., Che, Y.,...Owens, S. M. (2009). The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. Journal of Medicinal Chemistry, 52, 7301-7309.
6. Carroll, M. E., Gao, Y., Brimijoin, S., & Anker, J. J. (2011). Effects of cocaine hydrolase on cocaine self-administration under a PRschedule and during extended access (escalation) in rats. Psychopharmacology (Berl), 213, 817-829.
7. Celtic Pharma: (2012) Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation http://clinicaltrials.gov/ct2/show/NCT00633321.
8. Celtic Pharma: (2012) TA-NIC Nicotine Dependence http://www.celticpharma.com/theportfolio/ta-nic.html.
9. Cytos Biotechnology: (2012) New clinical study started with the nicotine vaccine NIC002 http://www.cytos.com/userfiles/file/Cytos_Press_E_101105.pdf.
10. Cytos Biotechnology: (2012) NIC002 (formerly CYT002-NicQb): a Novel Vaccine for Nicotine addition http://www.cytos.com/doc/NIC002_Nicaddiction_Facts_August07.pdf.
11. de Villiers, S. H., Lindblom, N., Kalayanov, G., Gordon, S., Baraznenok, I., Malmerfelt, A.,... Svensson, T. H. (2010). Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure. Vaccine, 28, 2161-2168.
12. de Villiers, S. H., Lindblom, N., Kalayanov, G., Gordon, S., Malmerfelt, A., Johansson, A. M., & Svensson, T. H. (2002). Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration, 69, 247-253.
13. Duryee, M. J., Bevins, R. A., Reichel, C. M., Murray, J. E., Dong, Y., Thiele, G. M., & Sanderson, S. D. (2009). Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine, 27, 2981-2988.
14. Fox, B. S., Kantak, K. M., Edwards, M. A., Black, K. M., Bollinger, B. K., Botka, A. J.,...Briner, T. J. (1996). Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Medicine, 2, 1129-1132.
15. Gao, Y., Orson, F. M., Kinsey, B., Kosten, T., & Brimijoin, S. (2010). The concept of pharmacologic cocaine interception as a treatment for drug abuse. Chemico-Biological Interactions, 187, 421-424.
16. Gentry, W. B., Ruedi-Bettschen, D., & Owens, S. M. (2009). Development of active and passive human vaccines to treat methamphetamine addiction. Human Vaccine, 5, 206-213.
17. Gentry, W. B., Ruedi-Bettschen, D., & Owens, S. M. (2010). Anti-(+)- methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction. Clininical Pharmacology and Therapeutics, 88, 390-393.
18. Godin, C. S., Shemesh-Davish, L., Sklair-Tavron, L., & Rosenstock, M. (2012) TV-1380 (Albumin-Fused Mutated Bche) Attenuates the Cardiovascular and Respiratory Effects Induced by Cocaine in Cynomolgus Monkeys http://www.avanzalaboratories.com/abstract/Teva%20Poster%20SOT%202010.pdf.
19. Gorelick, D. A. (1997). Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug and Alcohol Dependence, 48, 159-165.
20. Gorelick, D. A. (2012). Pharmacokinetic strategies for treatment of drug overdose and addiction. Future Medicinal Chemistry, 4, 227-243.
21. Gu, F., Langer, R., & Farokhzad, O. C. (2009). Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods in Molecular Biology, 544, 589-598.
22. Hatsukami, D. K., Jorenby, D. E., Gonzales, D., Rigotti, N. A., Glover, E. D., Oncken, C. A.,... Rennard, S. I. (2011). Immunogenicity and smokingcessation outcomes for a novel nicotine immunotherapeutic. Clininical Pharmacology and Therapeutics, 89, 392-399.
23. Hicks, M. J., De, B. P., Rosenberg, J. B., Davidson, J. T., Moreno, A. Y., Janda, K. D.,... Crystal, R. G. (2011). Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Molecular Therapy, 19, 612-619.
24. Kantak, K. M. (2003). Anti-cocaine vaccines: antibody protection against relapse. Expert Opinion in Pharmacotherapy, 4, 213-218.
25. Kinsey, B. M., Jackson, D. C., & Orson, F. M. (2009). Anti-drug vaccines to treat substance abuse. Immunology and Cell Biology, 87, 309-314.
26. Kinsey, B. M., Kosten, T. R., & Orson, F. M. (2010). Anti-cocaine vaccine development. Expert Rev Vaccines, 9, 1109-1114.
27. Kosten, T. R., Rosen, M., Bond, J., Settles, M., Roberts, J. S., Shields, J.,...Fox, B. (2002). Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine, 20, 1196-1204.
28. Li, Q. Q., Luo, Y. X., Sun, C. Y., Xue, Y. X., Zhu, W. L., Shi, H. S.,...Lu, L. (2011). A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. Journal of Neurochemistry, 119, 1271-1281.
29. Marsch, L. A. (1998). The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a metaanalysis. Addiction, 93, 515-532.
30. Martell, B. A., Mitchell, E., Poling, J., Gonsai, K., & Kosten, T. R. (2005). Vaccine pharmacotherapy for the treatment of cocaine dependence. Biological Psychiatry, 58, 158-164.
31. Montoya, I. (2008). [Immunotherapies for drug addictions]. Adicciones, 20, 111-115.
32. Montoya, I. D. & Vocci, F. (2008). Novel medications to treat addictive disorders. Current Psychiatry Reports, 10, 392-398.
33. Moreno, A. Y., Mayorov, A. V., & Janda, K. D. (2011). Impact of distinct chemical structures for the development of a methamphetamine vaccine. Journal of the American Chemical Society, 133, 6587-6595.
34. Nabi Pharmaceuticals: (2012) NicVAX ® (Nicotine Conjugate Vaccine) http://www.nabi.com/pipeline/pipeline.php?id=3.
35. Orson, F. M., Kinsey, B. M., Singh, R. A., Wu, Y., Gardner, T., & Kosten, T. R. (2008). Substance abuse vaccines. Annals of the New York Academy of Sciences, 1141, 257-269.
36. Peterson, E. C., & Owens, S. M. (2009). Designing immunotherapies to thwart drug abuse. Molecular Interventions, 9, 119-124.
37. Pravetoni, M., Keyler, D. E., Pidaparthi, R. R., Carroll, F. I., Runyon, S. P., Murtaugh, M. P.,...Pentel, P. R. (2012). Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochemical Pharmacology, 83, 543-550.
38. Pravetoni, M., Keyler, D. E., Raleigh, M. D., Harris, A. C., LeSage, M. G., Mattson, C. K.,...Pentel, P. R. (2011). Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochemical Pharmacology, 81, 1164-1170.
39. Pravetoni, M., Le, N. M., Harmon, T. M., Tucker, A. M., Portoghese, P. S., & Pentel, P. R. (2012). An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. Journal of Pharmacology and Experimental Therapeutics, 341, 225-232.
40. Selecta Biosciences: (2012) Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention http://www.selectabio.com/news/recent-news/Selecta-Biosciences-Initiates-Phase-1-Clinical-Study-of-SEL-068.cfm.
41. Stowe, G. N., Vendruscolo, L. F., Edwards, S., Schlosburg, J. E., Misra, K. K., Schulteis, G.,...Janda, K. D. (2011). A vaccine strategy that induces protective immunity against heroin. Journal of Medicinal Chemistry, 54, 5195-5204.
42. Substance Abuse and Mental Health Services Administration. (2011). Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS. Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011.
43. Treweek, J. B., Roberts, A. J., & Janda, K. D. (2011). Immunopharmacotherapeutic manifolds and modulation of cocaine overdose. Pharmacology Biochemistry and Behavior, 98, 474-484.
44. U.S.Food and Drug Administration (1999). Regulation of Biological Products. 42USC262 [On-line]. Available: http://www.fda.gov/RegulatoryInformation/Legislation/ucm149278.htm
45. Unknown: (2012) Swedish scientists working on Niccine, a vaccine to fight against http://healthvox.info/?p=33.
46. Volkow, N. D. (2010). Toward individualized treatment for substance abuse. Addiction Science and Clinical Practice, 5, 2.
47. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., & Farokhzad, O. C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clinical Pharmacology and Therapeutics, 83, 761-769.
48. Zheng, F., Yang, W., Ko, M. C., Liu, J., Cho, H., Gao, D.,...Zhan C.G. (2008). Most efficient cocaine hydrolase designed by virtual screening of transition states. Journal of the American Chemical Society, 130, 12148-12155.
49. Zheng, F., & Zhan, C. G. (2009). Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anti-cocaine medications. Future Medicinal Chemistry, 1, 515-528.